甲状腺癌总体预后良好，但尚无术前生化标记物被证明可以区分低风险和高风险疾病或预测对治疗的反应。我们回顾性回顾了 2006 年至 2022 年期间因甲状腺癌接受甲状腺手术的 162 名患者。术前测量了甲状腺球蛋白水平（Tg）。我们根据 ATA 指南对治疗的反应，将患者细分为低、中、高风险甲状腺癌。我们发现，随着术前 Tg 水平的升高，患者更有可能患有高风险疾病（p ​< ​0.01）。我们发现原发肿瘤大小和高风险组织学与术前 Tg 之间存在线性相关性 (p < 0.01)。术前 Tg 水平与初次手术治疗后的治疗反应显着相关。具体来说，随着术前 Tg 的增加，患者获得良好缓解的可能性较小 (p < 0.01)。我们的回顾性分析表明，术前 Tg 与 ATA 结构性复发风险和治疗反应显着相关，并且可能有潜力指导初始治疗和后续管理。由爱思唯尔公司出版。

Thyroid cancer has an overall favorable prognosis, but no pre-operative biochemical marker has been shown to distinguish between low and high-risk disease or predict response to therapy.We retrospectively reviewed 162 patients that underwent thyroid surgery for thyroid cancer between 2006 and 2022 in whom a pre-operative thyroglobulin level (Tg) was measured. We subdivided patients into low, intermediate and high-risk thyroid cancer and based on their response to therapy per ATA guidelines.We showed that as pre-operative Tg level increased, patients were more likely to have high-risk disease (p ​< ​0.01). We found a linear association between the primary tumor size and high-risk histology with pre-operative Tg (p ​< ​0.01). Pre-operative Tg level was significantly associated with response to therapy following initial surgical management. Specifically, as pre-operative Tg increases, patients were less likely to achieve an excellent response (p ​< ​0.01).Our retrospective analysis demonstrated that pre-operative Tg is significantly associated with ATA structural risk of recurrence and response to therapy and may have the potential to guide initial therapy and follow-up management.Published by Elsevier Inc.